Delving into the Latest Updates on MGI PHARMA Biologics, Inc. with Synapse

概览

关联

3

项与 MGI PHARMA Biologics, Inc. 相关的药物

Amolimogene bepiplasmid

靶点-

作用机制

免疫刺激剂

在研机构-

原研机构

MGI PHARMA Biologics, Inc.

在研适应症-

非在研适应症

肛门上皮内瘤变 [+3]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

ZYC-200

靶点

MC1R

作用机制

MC1R激动剂 [+1]

在研机构-

原研机构

MGI PHARMA Biologics, Inc.

在研适应症-

非在研适应症

哮喘 [+3]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

ZYC-500

靶点-

作用机制-

在研机构-

原研机构

MGI PHARMA Biologics, Inc.

在研适应症-

非在研适应症

单纯疱疹

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 MGI PHARMA Biologics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 MGI PHARMA Biologics, Inc. 相关的专利（医药）

登录后查看更多信息

3

项与 MGI PHARMA Biologics, Inc. 相关的文献（医药）

2005-06-15·Clinical Cancer Research1区 · 医学

Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

1区 · 医学

Article

作者: Urban, Robert G. ; Ryan, David P. ; Campos, Susana ; Nadler, Lee M. ; Neuberg, Donna ; Richardson, Paul G. ; Hedley, Mary L. ; Nealon, Patrick ; Beach, Kathleen ; Marshall, Blossom ; Boyajian, Richard ; Gilligan, Timothy D. ; Matulonis, Ursula ; Gribben, John G.

AbstractPurpose: The carcinogen activator cytochrome P450 1B1 (CYP1B1) is expressed on almost all human tumors with rare expression on normal tissues. Anti-CYP1B1–specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy.Experimental Design: ZYC300, a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-dl-lactide-coglycolide microparticles, was used in a phase I clinical trial to treat 17 patients with advanced stage, progressive cancer. ZYC300 was administered i.m. at a fixed dose of 400 μg every other week for up to 12 doses.Results: Thirteen patients received six vaccinations and five received all 12 doses. No significant adverse events were observed. Six patients developed immunity to CYP1B1, three of whom developed disease stabilization. All but 1 of 11 patients who did not develop immunity to CYP1B1 progressed and did not respond to salvage therapy. Five patients who developed immunity to CYP1B1 required salvage therapy for progressive metastatic disease and showed marked response to their next treatment regimen, most of which lasted longer than 1 year.Conclusions: The association between immunity to CYP1B1 and response to next salvage therapy was not expected. Because six of the seven patients who had clinical benefit regardless of the nature of salvage therapy had developed immunity to CYP1B1, it seems highly unlikely that this occurred by chance alone. Regardless of the mechanism(s) that induced tumor regression, these findings force us to rethink how the generation of antitumor immunity might be integrated into the treatment of cancer.

Handbook of ELISPOT

Use of Interferon-γ ELISPOT in Monitoring Immune Responses in Humans

Article

作者: Robert G. Urban ; Mark Matijevic

The interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay has become a useful tool for immunologists seeking to quantify immune responses on a per-cell basis. The assay is sensitive and allows for the enumeration of low-frequency T-cells. Many have applied this assay to clinical trials as a way to measure biological activity in a patient cohort. It is critical that each laboratory attempting to use the assay in their facility perform rigorous development and qualification work to establish an assay that suits their particular needs. This chapter serves as a demonstration of two practical and slightly different approaches to using the ELISPOT assay to monitor immune activity in the human periphery: (1) assays using whole samples of peripheral blood mononuclear cells with and without the use of additional antigen presenting cells and (2) assays using enriched T-cell populations. Detailed protocols and procedures will be covered, as well as a demonstration of results obtained from three separate applications.

Methods in Molecular Biology (Totowa, NJ, United States)

Use of interferon-γ ELISPOT in monitoring immune responses in humans

作者: Urban, Robert G. ; Matijevic, Mark

The interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay has become a useful tool for immunologists seeking to quantify immune responses on a per-cell basis.The assay is sensitive and allows for the enumeration of low-frequency T-cells.Many have applied this assay to clin. trials as a way to measure biol. activity in a patient cohort.It is critical that each laboratory attempting to use the assay in their facility perform rigorous development and qualification work to establish an assay that suits their particular needs.The authors demonstrate 2 practical and slightly different approaches to using the ELISPOT assay to monitor immune activity in the human periphery: (1) assays using whole samples of peripheral blood mononuclear cells with and without the use of addnl. antigen presenting cells and (2) assays using enriched T-cell populations.Detailed protocols and procedures are covered, as well as a demonstration of results obtained from 3 sep. applications.

100 项与 MGI PHARMA Biologics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 MGI PHARMA Biologics, Inc. 相关的转化医学

登录后查看更多信息